Analysts’ Viewpoint on Cannabinoids Market Scenario
Supportive government policies and legalization of cannabinoid products in several countries are encouraging companies operating in the cannabinoids market. Canada became the first G20 nation to legalize the use of cannabis sativa for medicinal & recreational purposes. The global cannabinoid market is driven by product advancements. Awareness about health benefits of cannabinoids products is rising among consumers. However, the global cannabinoids market is experiencing a slight contraction due to the high costs of these products. Hence, governments and private players are focusing on capitalizing on cannabinoid products. For instance, Organigram Holdings, Inc. made additional investments in Hyasynth Biologicals, Inc., a renowned biotechnology company.
Cannabinoids are derived from phytocannabinoids, endocannabinoids, and synthetic cannabinoids; and are used for medical applications. Major cannabinoids and minor cannabinoids are the two types of cannabinoids. Major cannabinoids include tetrahydrocannabinol and cannabidiol. Minor cannabinoids include cannabinoids, cannabidivarin, and cannabigerol. Cannabinoid synthesis in plants in small amounts is termed as minor cannabinoids. Rise in interest in the potential usage of cannabis in various medical conditions as well as research on the adverse health effects from use of cannabis is encouraging governments of countries across the globe to support the sale of CBD oil at hospital pharmacies and physician offices. This is projected to drive the global cannabinoids market in the near future.
Technological advancements have led to the introduction of new plant cloning techniques in the market. GW Pharmaceuticals launched its lead cannabinoid product Epidiolex in 2018. It is a pharmaceutical formulation comprising highly purified plant derived cannabidiol, for which the company retains global commercial rights.
The medical cannabis industry is expanding with advances in the use of cannabidiol (CBD). Usage of cannabidiol has increased due to rise in legalization of cannabidiol in various countries. Additionally, the FDA approval for CBD products for epilepsy treatment is promoting their usage in the pharmaceutical industry. Therefore, companies would continue to come up with medical solutions with improved CBD-based medicines. For instance, SanSal Wellness is working on the research & development of improved hemp genetics and innovation, providing uncompromising high quality hemp products to the global community. In 2019, the Government of Australia declared investment of US$ 3 Mn for research in medical cannabis. Thus, rise in research & development and investment in medical cannabinoids are likely to drive the global market.
Medical hashish is a popular herbal treatment used to treat unusual ailments. Around 104 chemical compounds called cannabinoids have been discovered in a hashish or marijuana plant, which can play an important role in the remedy of one-of-a-kind diseases. Tetrahydrocannabinol (THC) is the leading psychoactive cannabinoid discovered in hashish, which offers greater alleviation from aches and different signs & symptoms without the mind-altering outcomes of marijuana. CBD is probably used to lessen persistent ache by means of impacting endocannabinoid receptor activity, decreasing inflammation, and interacting with neurotransmitters. For instance, Sativex, an oil spray, is an aggregate of tetrahydrocannabinol (THC) and cannabidiol (CBD); and is permitted in many countries to treat aches associated with multiple sclerosis.
In terms of product, the global cannabinoids market has been classified into cannabidiol, tetrahydrocannabinol, and others. The cannabidiol segment accounted for major share of the global market in 2021. The segment is expected to expand at a CAGR of around 22% from 2022 to 2031. Cannabidiol is less psychoactive to neutralize the reactive oxygen species, which makes it a crucial contributor to anti-inflammatory effects. Cannabidiol is derived from hemp and marijuana; hence, it helps patients overcome anxiety and pain. Cannabis-infused products are also popular among end-users across the globe. Companies in the global cannabinoid market are focusing on increasing the manufacture of cannabidiol products that are safe for consumption.
Based on application, the global cannabinoids market has been divided into medical
and non-medical use. The non-medical use segment accounted for the largest share of the global market in 2021. The segment is expected to expand at a CAGR of about 19% from 2022 to 2031 due to the increase in usage of cannabis in food, cosmetics, and textile industries. CBD edibles such as gummies and cannabis-infused chocolate bars are increasingly popular among end-users. They possess antioxidant properties and help relieve stress and depression.
In terms of distribution channel, the global cannabinoids market has been divided into hospitals, retail pharmacies & stores, and online stores. The retail pharmacies & stores segment accounted for the largest share of the global market in 2021. The segment is expected to expand at a high CAGR of about 22% from 2022 to 2031. The number of retail pharmacies and stores selling cannabinoids products is increasing due to the legalization of cannabinoids in many countries. Companies in the cannabinoids market are developing innovative products to meet consumer demand. Hospital pharmacies and retail pharmacies are focusing on offering innovative cannabinoid products.
North America dominated the global market in 2021. The market in the region is projected to expand at a CAGR of about 18% from 2022 to 2031. The U.S. and Canada have legalized recreational cannabis, which is driving the market in the region. Rise in chronic diseases such as cancer, Alzheimer’s, and multiple sclerosis has boosted the demand for synthetic cannabinoids in surgeries and chemotherapies. Government support has encouraged local cannabis traders to invest in indoor facilities for cultivation. This is likely to boost the market in North America.
The market in Europe is anticipated to expand at a CAGR of about 37% during the forecast period. Large economies in Europe are moving toward liberalization of cannabinoids. The Netherlands is the most mature medical cannabis market in the region. Germany is the economic powerhouse of Europe, with a geriatric population of over 19 million; of this, 80% to 90% is covered under statutory health insurance, which makes up for the cost of medical cannabis.
The global cannabinoids market is consolidated with a small number of large companies accounting for majority of the share. Most of the firms are making significant investments in research and development activities. Expansion of product portfolios and mergers & acquisitions are the key strategies adopted by key players. Prominent players operating in the market include Mylan N.V. (Viatris Inc.), Alkem Labs, GW Pharmaceuticals plc, Tilray, Inc., Aurora Cannabis, Inc., Canopy Growth Corporation, and The Cronos Group.
Each of these players has been profiled in the cannabinoids market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. In addition, the report focuses on demand analysis of cannabinoids products.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 22.1 Bn |
|
Market Forecast Value in 2031 |
US$ 154.2 Bn |
|
Growth Rate (CAGR) |
22.2% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn for Value and Tons for Volume |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global cannabinoids market was valued at US$ 22.1 Bn in 2021
The global cannabinoids market is projected to generate revenue of US$ 154.2 Bn by 2031
The global cannabinoids market expanded at a CAGR of 25.1% from 2017 to 2021
The global cannabinoids market is anticipated to expand at a CAGR 22.2% from 2022 to 2031
Rise in awareness about benefits of cannabis in medical use and easy access to CBD oil through online platforms
North America is expected to account for the largest share of the global market during the forecast period.
Prominent players in the global cannabinoids market include Mylan N.V. (Viatris, Inc.), Alkem Labs, GW Pharmaceuticals plc, Tilray, Inc., Aurora Cannabis, Inc., Canopy Growth Corporation, The Cronos Group, The Supreme Cannabis Company, Inc., and Elixinol Global Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cannabinoids Market
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Cannabinoids Market Analysis and Forecast, 2017–2031
4.3.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Porter's Five Forces Analysis
5.2. PESTLE Analysis
5.3. Cannabis Genetics: Overview & Analysis
5.4. Regulatory Scenario, by Region/Globally
5.5. Pricing Analysis
5.6. List of key Competitors
5.7. COVID-19 Impact Analysis
5.8. Key Industry Development
6. Global Cannabinoids Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Cannabidiol
6.3.2. Tetrahydrocannabinol
6.3.3. Cannabinol
6.3.4. Others
6.4. Market Attractiveness Analysis, by Product Type
7. Global Cannabinoids Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospitals Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Stores
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Cannabinoids Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Medicinal Use
8.3.1.1. Chronic Pain
8.3.1.2. Neurological Disorders Management
8.3.1.3. Oncology
8.3.1.4. Others
8.3.2. Non-medical Use
8.4. Market Attractiveness Analysis, by Application
9. Global Cannabinoids Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cannabinoids Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2031
10.2.1. Cannabidiol
10.2.2. Tetrahydrocannabinol
10.2.3. Cannabinol
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospitals Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Stores
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Medicinal Use
10.4.1.1. Chronic Pain
10.4.1.2. Neurological Disorders Management
10.4.1.3. Oncology
10.4.1.4. Others
10.4.2. Non-medical Use
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By Distribution Channel
10.6.3. By Application
10.6.4. By Country
11. Europe Cannabinoids Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Cannabidiol
11.2.2. Tetrahydrocannabinol
11.2.3. Cannabinol
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospitals Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Stores
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Medicinal Use
11.4.1.1. Chronic Pain
11.4.1.2. Neurological Disorders Management
11.4.1.3. Oncology
11.4.1.4. Others
11.4.2. Non-medical Use
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Distribution Channel
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Cannabinoids Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Cannabidiol
12.2.2. Tetrahydrocannabinol
12.2.3. Cannabinol
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospitals Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Stores
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Medicinal Use
12.4.1.1. Chronic Pain
12.4.1.2. Neurological Disorders Management
12.4.1.3. Oncology
12.4.1.4. Others
12.4.2. Non-medical Use
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Japan
12.5.2. India
12.5.3. Australia & New Zealand
12.5.4. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Distribution Channel
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Latin America Cannabinoids Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Cannabidiol
13.2.2. Tetrahydrocannabinol
13.2.3. Cannabinol
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospitals Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Stores
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Medicinal Use
13.4.1.1. Chronic Pain
13.4.1.2. Neurological Disorders Management
13.4.1.3. Oncology
13.4.1.4. Others
13.4.2. Non-medical Use
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Distribution Channel
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Middle East & Africa Cannabinoids Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Cannabidiol
14.2.2. Tetrahydrocannabinol
14.2.3. Cannabinol
14.2.4. Others
14.3. Market Value Forecast, by Distribution Channel, 2017–2031
14.3.1. Hospitals Pharmacies
14.3.2. Retail Pharmacies
14.3.3. Online Stores
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Medicinal Use
14.4.1.1. Chronic Pain
14.4.1.2. Neurological Disorders Management
14.4.1.3. Oncology
14.4.1.4. Others
14.4.2. Non-medical Use
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. South Africa
14.5.2. Israel
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Distribution Channel
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Mylan N.V. (Viatris Inc.)
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Alkem Labs
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. GW Pharmaceuticals plc
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Tilray, Inc.
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Aurora Cannabis, Inc.
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Canopy Growth Corporation
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. The Cronos Group
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
List of Tables
Table 01: Global Cannabinoids Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Cannabinoids Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Cannabinoids Market Value (US$ Mn) Forecast, by Medicinal Use, 2017–2031
Table 04: Global Cannabinoids Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Cannabinoids Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Cannabinoids Market Analysis Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Cannabinoids Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2031
Table 08: North America Cannabinoids Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 09: North America Cannabinoids Market Revenue (US$ Mn) Forecast, by Medicinal Use, 2017–2031
Table 10: North America Cannabinoids Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Cannabinoids Market Analysis Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Cannabinoids Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2031
Table 13: Europe Cannabinoids Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Europe Cannabinoids Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Asia Pacific Cannabinoids Market Analysis Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Asia Pacific Cannabinoids Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2031
Table 17: Asia Pacific Cannabinoids Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Asia Pacific Cannabinoids Market Revenue (US$ Mn) Forecast, by Application (Medicinal Use), 2017–2031
Table 19: Asia Pacific Cannabinoids Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 20: Latin America Cannabinoids Market Analysis Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Latin America Cannabinoids Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2031
Table 22: Latin America Cannabinoids Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Latin America Cannabinoids Market Revenue (US$ Mn) Forecast, by Application (Medicinal Use), 2017–2031
Table 24: Latin America Cannabinoids Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Middle East & Africa Cannabinoids Market Analysis Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Middle East & Africa Cannabinoids Market Revenue (US$ Mn) Forecast, by Product Type, 2017–2031
Table 27: Middle East & Africa Cannabinoids Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Middle East & Africa Cannabinoids Market Revenue (US$ Mn) Forecast, by Application (Medicinal Use), 2017–2031
Table 29: Middle East & Africa Cannabinoids Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Cannabinoids Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Cannabinoids Market Value Share (%), by Region, 2020
Figure 03: Global Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 04: Global Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 05: Global Cannabinoids Market Value (US$ Mn), by Cannabidiol, 2017–2031
Figure 06: Global Cannabinoids Market Value (US$ Mn), by Tetrahydrocannabinol, 2017–2031
Figure 07: Global Cannabinoids Market Value (US$ Mn), by Cannabinol, 2017–2031
Figure 08: Global Cannabinoids Market Value (US$ Mn), by Others, 2017–2031
Figure 09: Global Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 10: Global Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 11: Global Cannabinoids Market Revenue (US$ Mn), by Medicinal Use, 2017–2031
Figure 12: Global Cannabinoids Market Revenue (US$ Mn), by Non-medical Use, 2017–2031
Figure 13: Global Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 14: Global Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 15: Global Cannabinoids Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 16: Global Cannabinoids Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 17: Global Cannabinoids Market Revenue (US$ Mn), by Online Stores, 2017–2031
Figure 18: Global Cannabinoids Market Value Share Analysis, by Region, 2020 and 2031
Figure 19: Global Cannabinoids Market Attractiveness Analysis, by Region, 2021–2031
Figure 20: North America Cannabinoids Market Analysis Value (US$ Mn) Forecast, 2017–2031
Figure 21: North America Cannabinoids Market Analysis Value Share Analysis, by Country, 2020 and 2031
Figure 22: North America Cannabinoids Market Analysis Attractiveness Analysis, by Country 2021–2031
Figure 23: North America Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 24: North America Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 25: North America Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 26: North America Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 27: North America Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 28: North America Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 29: Europe Cannabinoids Market Analysis Value (US$ Mn) Forecast, 2017–2031
Figure 30: Europe Cannabinoids Market Analysis Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 31: Europe Cannabinoids Market Analysis Attractiveness Analysis, by Country/Sub-region 2021–2031
Figure 32: Europe Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 33: Europe Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 34: Europe Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 35: Europe Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 36: Europe Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 37: Europe Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 38: Asia Pacific Cannabinoids Market Analysis Value (US$ Mn) Forecast, 2017–2031
Figure 39: Asia Pacific Cannabinoids Market Analysis Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 40: Asia Pacific Cannabinoids Market Analysis Attractiveness Analysis, by Country/Sub-region 2021–2031
Figure 41: Asia Pacific Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 42: Asia Pacific Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 43: Asia Pacific Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 44: Asia Pacific Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 45: Asia Pacific Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 46: Asia Pacific Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 47: Latin America Cannabinoids Market Analysis Value (US$ Mn) Forecast, 2017–2031
Figure 48: Latin America Cannabinoids Market Analysis Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 49: Latin America Cannabinoids Market Analysis Attractiveness Analysis, by Country/Sub-region 2021–2031
Figure 50: Latin America Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 51: Latin America Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 52: Latin America Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 53: Latin America Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 54: Latin America Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 55: Latin America Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 56: Middle East & Africa Cannabinoids Market Analysis Value (US$ Mn) Forecast, 2017–2031
Figure 57: Middle East & Africa Cannabinoids Market Analysis Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 58: Middle East & Africa Cannabinoids Market Analysis Attractiveness Analysis, by Country/Sub-region 2021–2031
Figure 59: Middle East & Africa Cannabinoids Market Value Share Analysis, by Product Type, 2020 and 2031
Figure 60: Middle East & Africa Cannabinoids Market Attractiveness Analysis, by Product Type, 2021–2031
Figure 61: Middle East & Africa Cannabinoids Market Value Share Analysis, by Application, 2020 and 2031
Figure 62: Middle East & Africa Cannabinoids Market Attractiveness Analysis, by Application, 2021–2031
Figure 63: Middle East & Africa Cannabinoids Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 64: Middle East & Africa Cannabinoids Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cannabinoids Market
